Brief: Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
05/12/2024 13:11
Dec 5 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* RYVU THERAPEUTICS ANNOUNCES DOSING OF THE FIRST PATIENT IN
THE
POTAMI-61 PHASE II STUDY OF RVU120 FOR THE TREATMENT OF PATIENTS
WITH MYELOFIBROSIS (MF)
Source text: ID:nPnbHGpJza
Further company coverage: RVU.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project